Division: Sports Medicine
Category: Early Intervention
MONOVISC is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g. acetaminophen. MONOVISC Hyaluronan may enhance the viscoelastic properties of synovial fluid to relieve pain and increase mobility
|High HA (Hyaluronic Acid) Concentration||High concentration maximize the potential for impacting osteoarthritic cell function and restoring native HA production.|
|High Molecular Weight||
Preclinical studies suggest that there is an optimal molecular weight (MW) of HA required to stimulate native HA production. 1
Optimal MW molecules bind strongly to synoviolcyte surface receptors, maximizing the stimulation of native HA.
|Non-Avian ultra-pure HA||MONOVISC is not derived from animal tissue. It has a very low residual protein content and can be prescribed to patients with known avian allergies.|
|Strong Safety Profile||MONOVISC has a very low rate of adverse events. The results of the safety analysis indicate that MONOVISC is well tolerated with an adverse event profile similar to saline injection.2|
All medical devices have associated risks. Please refer to the package insert and other labeling for a complete list of indications, contraindications, precautions and warnings. For further information on DePuy Synthes Products, please contact your local DePuy Synthes Representative.